DK2376499T3 - 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19,3,1,1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaencitratsalt - Google Patents

11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19,3,1,1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaencitratsalt Download PDF

Info

Publication number
DK2376499T3
DK2376499T3 DK09788621T DK09788621T DK2376499T3 DK 2376499 T3 DK2376499 T3 DK 2376499T3 DK 09788621 T DK09788621 T DK 09788621T DK 09788621 T DK09788621 T DK 09788621T DK 2376499 T3 DK2376499 T3 DK 2376499T3
Authority
DK
Denmark
Prior art keywords
salt
shows
hci
batch
ray diffraction
Prior art date
Application number
DK09788621T
Other languages
English (en)
Inventor
Cheng Hsia Angeline Lee
Anthony Deodaunia William
Brian Dymock
Original Assignee
Cti Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cti Biopharma Corp filed Critical Cti Biopharma Corp
Application granted granted Critical
Publication of DK2376499T3 publication Critical patent/DK2376499T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/22—Tricarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
    • C07D201/02—Preparation of lactams
    • C07D201/10—Preparation of lactams from cycloaliphatic compounds by simultaneous nitrosylation and rearrangement
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)

Claims (13)

1. Citratsalt af ll-(2-pyrrolidin-l-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19,3,1,1(2,6). 1(8,12)]heptacosa-l (25),2(26),3,5,8,10,12(27),16,21,23-decaen.
2. Salt ifølge krav 1, hvor saltet er krystallinsk.
3. Salt ifølge krav 1 eller 2, hvor saltet er l:l-saltet.
4. Salt ifølge et hvilket som helst af kravene 1 til 3 der viser på røntgendiffraktion en top på 2-theta-skalaen ved 22,4°±0,5°.
5. Salt ifølge krav 4 der også viser på røntgendiffraktion toppe på 2-theta-skalaen ved 10,2°±0,5° og 15,7°±0,5°.
6. Salt ifølge et hvilket som helst af kravene 1 til 5 der viser på røntgendiffraktion mindst fire toppe på 2-theta-skalaen valgt fra gruppen bestående af 7,8°±0,5°, 10,2°±0,5°, 14,2°±0,5°, 15,7°±0,5°, 16,8°±0,5°, 21,4°±0,5°, og 22,4°±0,5°.
7. Salt ifølge krav 6 der viser på røntgendiffraktion mindst 6 toppe på 2-theta-skalaen valgt fra gruppen bestående af 7,8°±0,5°, 10,2°±0,5°, 14,2°±0,5°, 15,7°±0,5°, 16,8°±0,5°, 21,4°±0,5°, og 22,4°±0,5°.
8. Salt ifølge krav 6 der viser på røntgendiffraktion toppe på 2-theta-skalaen ved 7,8°±0,5°, 10,2°±0,5°, 14,2°±0,5°, 15,7°±0,5°, 16,8°±0,5°, 21,4°±0,5°, og 22,4°±0,5°.
9. Salt ifølge krav 8 der også viser på røntgendiffraktion toppe på 2-theta-skalaen ved 10,9°±0,5°, 17,1°±0,5°, 23,3°±0,5°, 25,1°±0,5°, 25.8°±0,5°, og 27,5°±0,5°.
10. Salt ifølge krav 9 der også viser på røntgendiffraktion toppe på 2-theta-skalaen ved 7,2°±0,5°, 17,6°±0,5°, 18,5°±0,5°, 18,7°±0,5°, 20,7°±0,5°, 23,1°±0,5°, 24,2°±0,5°, 26,2°±0,5°, 26,9°±0,5°, 28,7°±0,5°, 29,3°±0,5°, 31,0°±0,5°, 32,4°±0,5°, 37,3°±0,5°, 38,6°±0,5°, 39,9°±0,5° og 41,6°±0,5°.
11. Farmaceutisk sammensætning omfattende et salt ifølge et hvilket som helst af kravene 1 til 10.
12. Salt ifølge et hvilket som helst af kravene 1 til 10 til anvendelse i behandling eller forebyggelse af en proliferativ lidelse.
13. Salt til anvendelse ifølge krav 12, hvor den proliferative lidelse er cancer.
DK09788621T 2008-12-11 2009-12-09 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19,3,1,1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaencitratsalt DK2376499T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12166808P 2008-12-11 2008-12-11
PCT/SG2009/000473 WO2010068181A1 (en) 2008-12-11 2009-12-09 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt

Publications (1)

Publication Number Publication Date
DK2376499T3 true DK2376499T3 (da) 2015-05-04

Family

ID=41666397

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09788621T DK2376499T3 (da) 2008-12-11 2009-12-09 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19,3,1,1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaencitratsalt

Country Status (24)

Country Link
US (2) US8980873B2 (da)
EP (1) EP2376499B1 (da)
JP (1) JP5669748B2 (da)
KR (1) KR101729918B1 (da)
CN (1) CN102282148B (da)
AR (2) AR074724A1 (da)
AU (1) AU2009325147B2 (da)
BR (1) BRPI0922736B1 (da)
CA (1) CA2746058C (da)
DK (1) DK2376499T3 (da)
ES (1) ES2536558T3 (da)
HK (1) HK1161877A1 (da)
HR (1) HRP20150428T1 (da)
IL (3) IL213418A0 (da)
MX (1) MX2011006206A (da)
MY (1) MY160005A (da)
NZ (1) NZ593223A (da)
PL (1) PL2376499T3 (da)
PT (1) PT2376499E (da)
RU (1) RU2527970C2 (da)
SG (1) SG171907A1 (da)
TW (1) TWI449705B (da)
WO (1) WO2010068181A1 (da)
ZA (1) ZA201104032B (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2376500T3 (pl) * 2008-12-11 2015-07-31 Cti Biopharma Corp Sól maleinianowa 11-(2-pirrolidyn-1-yloetoksy)-14,19-dioksa-5,7,26 triazatetracyklo[19.3.1.1(2,6).1(8,12)]heptakosa-1(25),2(26),3,5,8,10,12(27),16,21,23-dekaenu
BRPI0922736B1 (pt) 2008-12-11 2022-02-22 Cti Biopharma Corp Sal de citrato de 11-(2-pirrolidin-1-il-etóxi)-14,19-dioxa5,7,26-triaza-tetraciclo [19.3.1.1(2,6).1 (8,12)]heptacosa1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno, composição farmacêutica compreendendo este e uso deste
PL2837632T3 (pl) 2012-04-13 2017-01-31 Lianyungang Jinkang Hexin Pharmaceutical Co. Ltd. Pochodne triazabicyklo[3.2.1]oktanu użyteczne do leczenia chorób proliferacyjnych
CN105061467B (zh) * 2015-08-28 2017-08-25 苏州立新制药有限公司 一种帕克替尼的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
EP1390366B1 (en) * 2001-05-14 2005-08-31 Pfizer Products Inc. The citrate salt of 5,8,14,-triazatetracyclo(10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaene
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
RU2004116311A (ru) * 2001-11-29 2005-03-27 Пфайзер Продактс Инк. (Us) Сукцинатные соли 5,8,14-триазатетрацикло [10.3.1.02,11(04,9]гексадека- 2(11),3,5,7,9-пентаена и их фармацевтические композиции
KR101513492B1 (ko) * 2005-11-16 2015-04-20 에스*바이오 피티이 리미티드 헤테로알킬이 결합된 피리미딘 유도체
BRPI0922736B1 (pt) 2008-12-11 2022-02-22 Cti Biopharma Corp Sal de citrato de 11-(2-pirrolidin-1-il-etóxi)-14,19-dioxa5,7,26-triaza-tetraciclo [19.3.1.1(2,6).1 (8,12)]heptacosa1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno, composição farmacêutica compreendendo este e uso deste

Also Published As

Publication number Publication date
CA2746058A1 (en) 2010-06-17
AR114133A2 (es) 2020-07-22
US20150322084A1 (en) 2015-11-12
CN102282148A (zh) 2011-12-14
KR101729918B1 (ko) 2017-04-25
CN102282148B (zh) 2014-12-24
AU2009325147A1 (en) 2011-06-23
TW201028426A (en) 2010-08-01
MX2011006206A (es) 2011-07-20
BRPI0922736A2 (pt) 2017-10-31
IL289379A (en) 2022-02-01
RU2527970C2 (ru) 2014-09-10
WO2010068181A1 (en) 2010-06-17
ES2536558T3 (es) 2015-05-26
RU2011126173A (ru) 2013-01-20
BRPI0922736B1 (pt) 2022-02-22
PL2376499T3 (pl) 2015-07-31
JP2012511571A (ja) 2012-05-24
AU2009325147B2 (en) 2014-08-14
IL250310A0 (en) 2017-03-30
KR20110106344A (ko) 2011-09-28
BRPI0922736A8 (pt) 2021-11-09
AR074724A1 (es) 2011-02-09
SG171907A1 (en) 2011-07-28
HRP20150428T1 (en) 2015-06-19
CA2746058C (en) 2016-05-17
WO2010068181A8 (en) 2011-08-18
PT2376499E (pt) 2015-06-03
TWI449705B (zh) 2014-08-21
EP2376499A1 (en) 2011-10-19
HK1161877A1 (en) 2012-08-10
JP5669748B2 (ja) 2015-02-12
US8980873B2 (en) 2015-03-17
ZA201104032B (en) 2012-08-29
EP2376499B1 (en) 2015-02-25
IL213418A0 (en) 2011-07-31
US20110294831A1 (en) 2011-12-01
US9624242B2 (en) 2017-04-18
MY160005A (en) 2017-02-15
NZ593223A (en) 2013-08-30

Similar Documents

Publication Publication Date Title
US9624242B2 (en) 11-2(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
DK2376500T3 (da) 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaenmaleatsalt
CA2768210C (en) 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt
EP2976326A2 (en) Process for preparation of 2-chloro-n-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide solid forms
CA2993356C (en) Processes for preparing an fgfr inhibitor
CZ305096B6 (cs) Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice
WO2016004911A1 (en) A cocrystal of ivabradine hydrochloride and (r)-mandelic acid and its pharmaceutical composition
KR20220129495A (ko) 단백질 키나제 억제제로서의 헤테로고리 화합물의 결정형
WO2011039670A1 (en) Novel forms of (2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b] indole)
AU2016210725A1 (en) Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride